
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals Inc. demonstrates a robust financial outlook driven by significant cash inflows that enable further strategic deal-making and foster a unique compounding business model within the smid-cap biotechnology sector. Anticipated strong product launches for Filspari and Ohtuvayre, alongside ongoing growth from established revenue contributors, underline the potential for sustained revenue generation. Additionally, the combination of royalties, licensing payments, and the sale of Captisol material adds diverse revenue streams, enhancing the company's financial stability and growth prospects.
Bears say
The financial outlook for Ligand Pharmaceuticals Inc is tempered by concerns regarding potential underperformance of royalty assets and challenges related to the intellectual property durability of key products. Additionally, the likelihood of clinical-stage royalty assets gaining approval appears uncertain, raising apprehensions about the future commercial viability of these assets. Overall, there is a prevailing sentiment that forthcoming terms for partnerships may prove less favorable than previously anticipated, compounded by the risk that commercial partners may encounter unforeseen obstacles.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares